Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2024-10-29 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯2024年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2024 Third Quarter Report" of 普莱柯生物工程股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the third quarter of 2024. The report explicitly states it is unaudited and covers the period from the start of the quarter to the end of the quarter (3 months). The length of the document (13,802 characters) and the presence of substantive financial data confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-10-29 Chinese
普莱柯关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 普莱柯生物工程股份有限公司 regarding the approval and issuance of a new veterinary drug registration certificate by the Ministry of Agriculture and Rural Affairs of China. It details the new drug's name, classification, components, usage, development background, and expected impact on the company. The document is relatively short (1313 characters) and serves as a formal notification of a regulatory approval event rather than a detailed financial or operational report. There are no financial statements, earnings data, or management discussions typical of annual or interim reports. It is not a call transcript, capital update, or governance information. The content fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about a new product approval without fitting into more specific categories like earnings, management changes, or capital changes.
2024-10-09 Chinese
普莱柯关于股份回购进展情况的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from 普莱柯生物工程股份有限公司 regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and the purpose of the repurchase (employee stock ownership plan or equity incentives). The document references regulatory guidelines on share repurchases and provides updates on the implementation status. It is not a full financial report, earnings release, or management discussion, but a specific update on share buyback activity. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is short and focused solely on share repurchase progress, confirming this classification with high confidence.
2024-10-08 Chinese
普莱柯2024年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement from an extraordinary shareholders' meeting (临时股东大会决议公告) held on September 19, 2024. It details the meeting attendance, voting results on a specific proposal regarding the use of idle raised funds for cash management, and includes legal witness statements confirming the legality and validity of the meeting and resolutions. The content focuses on the announcement of voting results from a shareholders' meeting rather than the meeting materials or the full report. The document length is short (1428 characters), and it is clearly an official announcement of voting results rather than a full report or presentation. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-09-19 Chinese
北京德恒律师事务所关于普莱柯生物工程股份有限公司2024年第三次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality of the procedures and validity of resolutions passed at a company's 2024 third extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the shareholders' meeting. It does not contain financial statements or financial performance data, nor is it a report or announcement of financial results. Instead, it is a legal opinion on the shareholders' meeting process and resolutions. This type of document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official validation and legality of shareholder voting outcomes at a general meeting.
2024-09-19 Chinese
普莱柯2024年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as "2024 年第三次临时股东大会会议资料" which translates to "2024 Third Extraordinary General Meeting (EGM) Materials". It contains detailed information about the meeting organization, voting procedures, agenda, and a specific proposal regarding the use of idle raised funds for cash management. The content is clearly intended as materials for a shareholders meeting, including procedural rules and agenda items, rather than a report or announcement of results. The document length is 4313 characters, which is relatively short but contains substantive meeting materials, not just an announcement or a brief notice. Therefore, it fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. It is not an announcement of voting results (DVA), nor a report publication announcement (RPA), nor a regulatory filing (RNS). Hence, the classification is AGM-R with high confidence.
2024-09-09 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.